Select therapeutic use:
Indications for PREMARIN VAGINAL CREAM:
Atrophic vaginitis. Kraurosis vulvae. Moderate-to-severe dyspareunia due to menopause.
Atrophic vaginitis or Kraurosis vulvae: 0.5–2g/day intravaginally cyclically (3 weeks on, 1 week off). Moderate-to-severe dyspareunia: 0.5g intravaginally twice weekly (eg, Mon. & Thurs.) continuously or 0.5g/day intravaginally cyclically (3 weeks on, 1 week off). Reevaluate periodically.
Known, suspected, or history of breast cancer, except in appropriately selected patients being treated for metastatic disease. Known or suspected estrogen-dependent neoplasia. Undiagnosed abnormal genital bleeding. Pulmonary embolism/DVT (active or history of). Arterial thromboembolism (eg, stroke, MI; active or history of). Liver dysfunction or disease. Protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders. Known or suspected pregnancy (Cat.X).
Not for prevention of cardiovascular disease. Use for shortest duration consistent with treatment goals and risks. Reevaluate periodically. Patients with an intact uterus should almost always receive a progestin with systemic estrogens to avoid endometrial hyperplasia. Discontinue if cardiovascular events occur or are suspected; if jaundice occurs; and during immobilization or at least 4–6 weeks before surgery associated with thromboembolism. Hepatic dysfunction. Conditions aggravated by fluid retention. Gallbladder disease. Bone disease associated with hypercalcemia. Hereditary angioedema. Do initial complete physical and repeat annually (include BP, mammogram, PAP smear). Adolescents. Nursing mothers: not recommended.
See literature. Increased risk of cardiovascular events, estrogen-dependent carcinoma, gallbladder disease, thromboembolic disorders, hepatic tumors. GI upset, breakthrough bleeding, edema, weight changes, mastodynia, hypertension, depression, anaphylactic reactions, angioedema, intolerance to contact lenses.
Tabs 0.3mg, 0.625mg, 1.25mg—100, 1000
Cream—42.5g (w. applicator)